Retroperitoneal lymph node dissection: a promising alternative for treating clinical stage II A/B seminomas ?

Clinical stage II A/B seminomas, a type of testicular cancer, are typically managed with chemotherapy or radiotherapy. While effective, these treatments are associated with significant short- and long-term toxicities, which increase the risks of cardiovascular complications and secondary cancers. In this context, retroperitoneal lymph node dissection (RPLND)—a surgical procedure that removes retroperitoneal lymph nodes—has emerged as a potentially less toxic alternative. Drawing from a recent systematic review and meta-analysis, this article examines the efficacy and safety of RPLND as a first-line treatment for clinical stage II A/B seminomas.  

Is RPLND an effective and safe option for treating clinical stage II A/B seminomas?